Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mometasone Furoate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 4/20 | 1.00 |
| ▸ | PGR | P06401 | 4/20 | 1.00 |
| ▸ | AR | P10275 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 4/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.64 |
| ▸ | CNR1 | P21554 | 2/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.64 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mometasone Furoate SCHEMBL4568 | 1.00 | CYP3A4 (1.00) | CYP3A4NR3C1LMNAABCB11PGR | |
| Mometasone Furoate SCHEMBL8430908 | 1.00 | CYP3A4 (1.00) | CYP3A4NR3C1LMNAABCB11PGR | |
| Mometasone Furoate SCHEMBL12996648 | 1.00 | CYP3A4 (1.00) | CYP3A4NR3C1LMNAABCB11PGR | |
| Mometasone Furoate SCHEMBL4896227 | 1.00 | CYP3A4 (1.00) | CYP3A4NR3C1LMNAABCB11PGR | |
| Mometasone Furoate SCHEMBL8826257 | 1.00 | CYP3A4 (1.00) | CYP3A4NR3C1LMNAABCB11PGR | |
| Mometasone Furoate SCHEMBL7436523 | 1.00 | CYP3A4 (1.00) | CYP3A4NR3C1LMNAABCB11PGR | |
| Mometasone Furoate SCHEMBL25382496 | 1.00 | CYP3A4 (1.00) | CYP3A4NR3C1LMNAABCB11PGR | |
| Mometasone Furoate SCHEMBL13026146 | 1.00 | CYP3A4 (1.00) | CYP3A4NR3C1LMNAABCB11PGR | |
| Mometasone Furoate SCHEMBL600107 | 1.00 | CYP3A4 (1.00) | CYP3A4NR3C1LMNAABCB11PGR | |
| Mometasone Furoate SCHEMBL4484 | 1.00 | CYP3A4 (1.00) | CYP3A4NR3C1LMNAABCB11PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3400214-B1 | DRY POWDER INHALER COMPOSITIONS OF 7-AZONIABICYCLO[2.2.1]HEPTANE DERIVATIVES | THERON PHARMACEUTICALS INC (US) | 2024-03-13 | — | — | EP | disclosed |
| US-10918601-B2 | Spray-dried pharmaceutical compositions comprising active agent nanoparticles | BESINS HEALTHCARE LUXEMBOURG SARL (LU) | 2021-02-16 | — | — | US | disclosed |
| US-20200390706-A1 | SPRAY-DRIED PHARMACEUTICAL COMPOSITIONS COMPRISING ACTIVE AGENT NANOPARTICLES | BESINS HEALTHCARE LUXEMBOURG SARL (LU) | 2020-12-17 | — | — | US | disclosed |
| US-10835514-B2 | Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives | THERON PHARMACEUTICALS, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| EP-2964199-B1 | DRY PHARMACEUTICAL COMPOSITIONS COMPRISING ACTIVE AGENT NANOPARTICLES BOUND TO CARRIER PARTICLES | BESINS HEALTHCARE LU SARL (LU) | 2020-04-22 | — | — | EP | disclosed |
| US-20190298690-A1 | DRY POWDER INHALER COMPOSITIONS OF 7-AZONIABICYCLO[2.2.1]HEPTANE DERIVATIVES | THERON PHARMACEUTICALS, INC. | 2019-10-03 | — | — | US | disclosed |
| EP-3501521-A1 | PREVENTION OF AND RECOVERY FROM DRUG-INDUCED OTOTOXICITY | Otonomy, Inc. (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20180036231-A1 | PREVENTION OF AND RECOVERY FROM DRUG-INDUCED OTOTOXICITY | OTONOMY, INC. | 2018-02-08 | — | — | US | disclosed |
| US-20130045957-A1 | Prevention of and Recovery from Drug-Induced Ototoxicity | OTONOMY, INC. (US) | 2013-02-21 | — | — | US | disclosed |
| WO-2011136754-A1 | A MEDICAMENT DEVELOPED FOR THE TREATMENT OF RESPIRATORY DISEASES | BILGIC MAHMUT (TR) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045957-A1 | Prevention of and Recovery from Drug-Induced Ototoxicity | OTC, SLC26A4, ALDH1A3 | NR3C1 655/4885CYP3A4 2821/4885LMNA 1276/4885 |
| US-20190298690-A1 | DRY POWDER INHALER COMPOSITIONS OF 7-AZONIABICYCLO[2.2.1]HEPTANE DERIVATIVES | CHRM2, CHRM3, CHRM1 | NR3C1 342/4885CYP3A4 234/4885LMNA 4425/4885 |
| US-20180036231-A1 | PREVENTION OF AND RECOVERY FROM DRUG-INDUCED OTOTOXICITY | OTC, SLC26A4, ALDH1A3 | NR3C1 655/4885CYP3A4 2821/4885LMNA 1276/4885 |
| US-10835514-B2 | Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives | CHRM2, CHRM3, CHRM1 | NR3C1 342/4885CYP3A4 234/4885LMNA 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.